Meta Platforms
META
Taiwan Semiconductor
TSM
Amazon
AMZN
Apple
AAPL
NVIDIA
NVDA
US Stock MarketDetailed Quotes
LTRN Lantern Pharma
- 3.190
- +0.030+0.95%
Close Dec 3 16:00 ET
- 3.350
- +0.160+5.02%
Post 19:55 ET
34.40MMarket Cap-1792P/E (TTM)
3.380High3.160Low56.19KVolume3.340Open3.160Pre Close185.37KTurnover0.71%Turnover RatioLossP/E (Static)10.78MShares11.99052wk High1.29P/B25.40MFloat Cap2.79052wk Low--Dividend TTM7.96MShs Float24.840Historical High--Div YieldTTM6.96%Amplitude2.380Historical Low3.298Avg Price1Lot Size
Lantern Pharma Stock Forum
Sign in to post a comment
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
7
3
1
$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE
$Lantern Pharma (LTRN.US)$
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...
$Lantern Pharma (LTRN.US)$
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...
1
$Lantern Pharma (LTRN.US)$ Reuters· 2 mins ago
Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
1
$Lantern Pharma (LTRN.US)$ Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients
$China Pharma (CPHI.US)$ $Bright Minds Biosciences (DRUG.US)$ $Lantern Pharma (LTRN.US)$ $Cytosorbents (CTSO.US)$ $Intensity Therapeutics (INTS.US)$ $Multi Ways (MWG.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $X3 Holdings (XTKG.US)$ $Protagenic Therapeutics (PTIX.US)$ $GRI Bio (GRI.US)$ $Paranovus Entertainment Technology (PAVS.US)$ $VSee Health (VSEE.US)$
📊⚡️📊
📊⚡️📊
2
1
$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE
$Hall Of Fame Resort & Entertainment (HOFV.US)$ $Vera Bradley (VRA.US)$ $Lantern Pharma (LTRN.US)$ $Passage Bio (PASG.US)$ $Sadot (SDOT.US)$ $EDC Publishing (EDUC.US)$ $SHL Telemedicine (SHLT.US)$ $Altamira Therapeutics (CYTO.US)$ $Indaptus Therapeutics (INDP.US)$ $QT Imaging (QTI.US)$ $MediaCo (MDIA.US)$ $Edesa Biotech (EDSA.US)$ $Expion360 (XPON.US)$ $Tevogen Bio Holdings (TVGN.US)$
2
$Lantern Pharma (LTRN.US)$
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
• Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
• This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors)....
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
• Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
• This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors)....
No comment yet
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
AhmadFH : Thanks Jag
71580478 : love it, thanks! what do you think about SHIM?
JMK47 : thanks for all your effort